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Abstract
Background: Lymphatic vessel spread is considered a major route for head and neck squamous cell carcinoma
metastasis. Formation of new lymphatic vessels could facilitate the process, raising the malignant potential of these
tumours. Recent identification of lymphatic markers allows the study of the lymphangiogenesis phenomenon. We
searched for molecular events involved in the lymphangiogenic process that could have prognostic value in
laryngeal/pharyngeal carcinoma patients.
Methods: 104 paraffin-embedded pharyngeal/laryngeal tumour samples were studied. Immunohistochemical
analysis of podoplanin and double immunofluorescence analysis of Ki-67 and D2-40 were performed. Lymph vessel
density (inside the tumour mass, at its periphery or considered as a whole) and the presence of tumour emboli
inside lymphatics were recorded. The proliferative state of endothelial lymphatic cells was evaluated.
Results: Lymphatic vessels were detected inside the tumour mass (75%) and in the surrounding tissue (80%); some
of them in a proliferative state. Tumour emboli were detected in a high proportion of the cases (45%). Lymphatic
vessel density was higher in the pharyngeal cases (p = 0.0029), in greater size (p = 0.039), more advanced stage
primary tumours (p = 0.006) and in carcinomas of patients with affected nodes (p = 0.019). The presence of
tumour emboli and a high global vessel density were indicators of poor prognosis (recorded as death from
tumour) in the laryngeal group (p = 0.015 and p = 0.027, respectively), but notably not in the pharyngeal one.
Interestingly, high global vessel density showed a negative prognostic value among pathologically staged N0
laryngeal carcinomas (p = 0.03).
Conclusions: The lymphangiogenic process correlated with aggressive tumour features (pN category, tumour size,
tumour stage), but might play different roles in tumours arising from different anatomic sites.
Our results suggest that detection of tumour emboli and assessment of global vessel density using the D2-40 anti-
body, may be useful in the clinical practice, as predictors of reduced survival among pN0 laryngeal carcinoma
patients.
Background
Head and neck squamous cell carcinoma (HNSCC)
remains a significant cause of morbidity and mortality,
afflicting 500.000 new cases worldwide each year[1]. The
single most adverse independent prognostic factor for
patients with HNSCC is the involvement of regional
lymph nodes, but its accuracy could be improved.
Invasion of cells into the surrounding tissue and the
destruction of normal tissue architecture are two hall-
marks of malignant tumours. Lymphatic vessels serve as
the primary conduit for malignant tumour cell to regio-
nal lymph nodes[2]. In recent years, increasing evidence
support that lymphangiogenesis is involved in the pro-
cess of lymphatic spread in HNSCC. However, whether
cancer cells can metastasize by expansion and invasion
of preexisting peritumoural lymphatics, or by the forma-
tion and invasion of new lymphatics within tumours
remains an unsolved question due to the difficulty in
distinguishing lymphatics from blood vessels[3-8].
Recently, several lymphatic endothelium markers were
identified and the most reliable one among them is
podoplanin, which is recognised by the monoclonal D2-
40 antibody with a high specificity and sensitivity [9-11].
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Using the D2-40 antibody in this study, the presence
and density of lymphatic vessels were determined and
quantified in laryngeal/pharyngeal carcinomas, and their
potential prognostic values were assessed.
Methods
Patients
Paraffin-embedded tissues from 104 patients with phar-
yngeal or laryngeal squamous cell carcinoma (Table 1)
who underwent resection of their tumours at the Hospi-
tal Universitario Central de Asturias (HUCA) (2000 -
2006) were obtained from the Pathology Department.
Having a balanced number of cases for every clinico-
pathologic category was one of the patient inclusion cri-
teria. Prior to the start the study was evaluated for
approval according to the institutional review board’s
guidelines on ethical procedures. None of the patients
had received radio/chemotherapy prior to resection or
were thought to have distant metastasis at the time of
diagnosis. Mean follow-up periods are shown in Table
1. Endpoints examined were nodal involvement, disease
specific and overall survival.
Immunohistochemical detection of lymphatic vessels
4 μm formalin-fixed paraffin-embedded sections were
incubated overnight at 54-56°C, deparaffinized in xylene
and rehydrated through decreasing graded ethanol solu-
tions. After endogenous peroxidase activity suppression
(3% hydrogen peroxide, 10 min) and antigen retrieval
(boiling in 10 mM citrate buffer, pH 6.0), immunostain-
ing was performed with D2-40 mouse monoclonal anti-
body against human podoplanin (M2A antigen,
Covance, California, USA) (1:100 dilution, 4°C, overnight
in a humid chamber). Staining was done by using the
DakoCytomation Envision Plus peroxidase mouse sys-
tem. The stained protein was visualized using the DAB
solution (Dako), and lightly counterstained with Mayers-
haematoxilyn.
To ascertain the specificity of the antibody immunor-
eactivity, a negative control was carried out by exclusion
of the primary antibody. In this case, immunolabeling
was completely abolished.
Evaluation of staining
Quantitative analysis of the intratumoural and peritu-
moural lymphatic vessel density was performed by two
independent observers (DGC and MVG) in a blinded
fashion. Three fields with the highest lymphatic vascular
density were identified (Olympus BX-51 microscope;
x100 magnification), and the vessels were counted (×400
magnification) both within the tumour area (intratu-
moural lymphatic density; ILD) and within an area 500
μm from the tumour border (peritumoural lymphatic
density; PLD). Lymphatic vessel density (LVD),
regardless of the vessel location with respect to the
tumour, was also considered. Lymphatic density was
defined as the number of lymphatic vessels per mm2.
Table 1 Clinicopathologic features of the laryngeal/
pharyngeal squamous cell carcinoma patients and their
primary tumours (N= 104)
Clinicopathologic feature N° cases (%)
Age Mean 60 (33-86)
Sex
Male 98 (94.2)
Female 6 (5.8)
Tumour site
Hypopharynx 18 (17.5)
Oropharynx 31 (30.1)
Glottis 30 (29.1)
Supraglottis 24 (23.3)
T category
1 19 (18.3)
2 20 (19.2)
3 30 (28.9)
4 35 (33.6)
N category
0 47 (45.2)
1 8 (7.7)
2 41 (39.4)
3 8 (7.7)
Degree of differentiation
Well 48 (49)
Moderate 32 (32.6)
Poor 18 (18.4)
Tumour stage (TNMa)
I 18 (18.18)
II 10 (10.10)
III 14 (14.14)
IV 57 (57.58)
Status
Alive without tumour 49 (47)
Alive with tumour 3 (3)
Death of tumour 34 (33)
Death other causes 18 (17)
Recurrence
No 66 (66)
Yes 34 (34)
Toxic habits
Cigarette smoking 103 (99)
Alcohol consumption 91 (88)
Mean follow up (months) (range)
Whole population 23 (10 - 67)
Larynx 26 (9 - 67)
Pharynx 20 (10 - 66)
aTNM staging system of the International Union Against Cancer - 6th Edition
[20].
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We also evaluated invasion of the podoplanin-positive
lymphatic vessels by cancer cells. Lymphatic invasion
(LI) was considered to be present if at least one tumour
cell cluster (a tumour embolus) was clearly visible inside
a podoplanin-positive vessel. Cases were classified as LI
positive or negative depending on the presence or
absence of tumour emboli, respectively.
Immunofluorescence study
Ten representative cases were selected on the basis of the
images of the lymphatic vessels obtained in D2-40 IHC.
For double immunostaining, deparaffined and rehydrated
sections were rinsed in 0.05 M Tris-buffered saline (TBS;
pH 7.5) containing 0.1% bovine serum albumin and 0.2%
Triton X-100. Endogenous peroxidase activity and non-
specific binding were blocked with 3% H202 and 50%
fetal calf serum (Sigma), respectively, and the sections
were incubated overnight with the primary antibodies in
a humid chamber at 4°C: mouse D2-40 (M2A antigen,
Covance, California, USA) and rabbit anti-ki67 (Abcam
ab833). After the incubation with the primary antibodies,
sections were incubated for 1 hr at room temperature
with Texas red-labelled sheep anti-rabbit immunoglobu-
lin G (IgG) and fluorescein isothiocyanate-conjugated
sheep anti-mouse IgG, both diluted at 1:100 (Amersham).
Finally, tissue sections were photographed with a confo-
cal-laser scanning microscope (Bio-Rad MR-600; Servicio
de Proceso de Imágenes de la Universidad de Oviedo).
Statistical analysis
For statistical purposes, clinicopathological features were
dichotomized as: pT category: 1-2, 3-4; pN category: N0,
N1-3; TNM stage: I-II, III-IV. The molecular data distrib-
uted among the different clinical groups of tumours were
tested for significance employing the c2 test for categori-
cal variables and t-Student/ANOVA or Mann Whitney/
Kruskal-Wallis tests for parametric and non parametric
continuous variables, respectively. Survival curves (dis-
ease-specific and overall) were calculated using the
Kaplan-Meier product limit estimate. Differences
between survival times were analyzed by the log-rank
method. Multivariate Cox proportional hazards models
were used to examine the relative impact of either vari-
ables demonstrated to be statistically significant in uni-
variate analysis or those variables likely to have an effect
on the outcome. P-values < 0.05 (based on two-tailed sta-
tistical analysis) were considered statistically significant.
All the statistical analyses were performed with the statis-
tical software SPSS 12.0 (SPSS, Inc., Chicago, IL).
Results
Results are reported following the REMARK guidelines
(REporting recommendations for tumor MARKer prog-
nostic studies)[12].
Lymphatic density quantification
Immunohistochemical detection of podoplanin with D2-
40 antibody shows strong specific reactivity with lym-
phatic endothelial cells, while the endothelial cells of
blood vessels show no signal (Figure 1A, E).
D2-40-positive lymphatic vessels could be identified
between islands of neoplastic epithelium (Figure 1B, F)
and at the tumour periphery (Figure 1C, G). Podoplanin
expression was also detected in tumour cells at the
tumour border (Figure 1B-C).
The percentages of the cases with positive lymphatic
vessel stainings, locations of the positive standings (ILD,
PLD or LVD), mean values, and score ranges in the 104
HNSCC, 54 laryngeal and 50 pharyngeal carcinoma
samples are summarized in Tables 2, 3 and 4.
Proliferating lymph vessels
Double immunofluorescence assay was performed with
D2-40 and the proliferation marker ki-67 in ten repre-
sentative cases. Vessels were deemed positive for prolif-
eration when they harboured at least one ki-67 positive
cell (Figure 2A-L) and were observed inside the tumour
mass or in its periphery.
Lymphatic invasion (LI)
Podoplanin-positive carcinoma cells could be visualized
inside lymph vessels (irrespective of vessel location) in 43%
of the cases (44/103, LI positive) (Figure 1D, H). Figure 2M-
P shows the proliferation state (ki-67) of a D2-40 positive
tumour mass inside a lymphatic vessel (LI positive case).
Correlations with clinicopathologic features
Considering the whole series for analysis, higher mean
ILD, PLD and LVD values were significantly associated
with greater tumour size, lymph node metastasis,
advanced tumour stage and pharyngeal tumour site
(Table 2). Tables 3 and 4 summarize ILD, PLD and
LVD mean values and LI distribution among clinico-
pathological features in laryngeal and pharyngeal carci-
nomas, respectively. Of note, while no association was
found in the pharyngeal group, LVD correlated with
greater tumour size and more advanced tumour stage
within the laryngeal population (p < 0.05, each).
The normal glottis is a particularly interesting site,
since it is a lymph vessel free region. In our series, 13
out of the 29 glottic cases (45%) showed lymphatics
within the tumour mass, 3 of which were T1 tumours.
Importantly, the presence of tumour emboli (lympha-
tic invasion) correlated with anatomic site (28% in laryn-
geal tumours vs. 58% in pharyngeal tumours; p = 0.002)
and were more frequently observed in tumours of
patients with affected lymph nodes (p = 0.001), in
greater size tumours (p = 0.006) and in more advanced
stage tumours (p = 0.000).
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Figure 1 Immunohistochemical identification of lymphatic vessels. Immunohistochemical identification of lymphatic vessels using D2-40
antibody against podoplanin in an oropharyngeal (A) and a supraglottic tumour (E). Detection of intratumoural lymphatics in an oropharyngeal
(B) and a supraglottic tumour (F). Detection of peritumoural lymphatics in a supraglottic tumour. The basal layer of the epithelium and the
margin of the tumour mass gave positive signal for podoplanin (C). Detection of peritumoural lymphatics in a glottic tumour that stained
positive for podoplanin (G). Example of one representative podoplanin positive tumour cell embolus inside a podoplanin positive lymphatic
vessel of an oropharyngeal (D) and a supraglottic carcinoma (H). Scale bar, 250 μm.
Table 2 Correlations between lymphatic vessel density and clinicopathologic features in the HNSCC series (N = 104)
ALL CASES ILD PLD LVD Lymphatic Invasion
Frequency 75% (78/104) 80% (83/104) 94% (98/104) 42.72% (44/103)
Mean (S.E.) 14.8 (1.33) 22.0 (1.59) 22.3 (1.19)
Score range 0-78.4 0-82.2 0-79.3
N Mean range p# N Mean (S.E) p¥ N Mean (S.E) p¥ Absent Present Total p*
Anatomic site
Pharynx 50 63.34 0.0004 50 27.41 (2.57) 0.0072 50 26.47 (1.92) 0.0029 21 29 50 0.002
Larynx 54 42.46 54 18.47 (2.03) 54 18.98 (1.56) 38 15 53
Total 104 104 104 59 44 103
pT
T1-2 39 39.09 0.0000 39 19.19 (2.47) 0.099 39 19.20 (2.03) 0.039 29 10 39 0.006
T3-4 65 60.55 65 24.91 (2.21) 65 24.61 (1.60) 30 34 64
Total 104 104 104 59 44 103
Nodal involvement
Free 47 42.44 0.0020 47 18.60 (2.37) 0.0230 47 19.34 (1.67) 0.0190 35 12 47 0.001
Affected 57 60.80 57 26.20 (2.27) 57 25.24 (1.82) 24 32 56
Total 104 104 104 59 44 103
Tumour Stage
I-II 28 32.98 0.0001 28 14.67 (2.44) 0.0010 28 16.89 (2.25) 0.0060 24 4 28 0.0000
III-IV 71 56.71 71 25.83 (2.14) 71 24.76 (1.57) 31 38 69
Total 99 99 99 55 42 97
Recurrence
No 66 50.98 0.8167 66 20.29 (2.17) 0.0729 66 21.15 (1.54) 0.1649 38 27 65 0.8050
Yes 34 49.57 34 26.86 (2.78) 34 25.04 (2.47) 19 15 34
Total 100 100 100 57 42 99
ILD, Intratumoural Lymphatic Density; PLD, Peritumoural Lymphatic Density; LVD, Lymphatic Vessel Density
S.E., Standard Error
p# (U Mann-Whitney); p¥ (t Student); p* (chi square)
Frequencies (cases with lymph vessels), mean values and score ranges of ILD, PLD and LVD in the whole series (N=104). Comparison of mean ILD, PLD and LVD
values among different categories of clinico-pathological features. Distribution of tumours according to lymphatic invasion (LI) and clinicopathological features.
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Survival analysis
The five-year disease specific and overall survival rates
for the whole population were 52% and 28%, respectively.
As expected, tumours arising in the larynx, those with
T1-2 category, stage I-II and patients without lymph
node involvement, had a better prognosis (p < 0.05).
For the survival analysis, lymphatic vessel variables
(ILD, PLD, LVD) were categorized into high vessel den-
sity cases vs. the rest, attending to the median value of
the lymph vessel density in the positive population
(Table 5). In this way, a high LVD (irrespective of vessel
location) had a negative impact on disease specific survi-
val (p = 0.045) and on overall survival (p = 0.0564). In
addition, disease specific (Figure 3A) and overall survival
were worse for patients with tumour emboli within the
vessels (LI positive) (p = 0.045 and p = 0.0312, respec-
tively). Importantly, these results were observed for the
laryngeal tumours (high LVD (p = 0.027), presence of
emboli; p = 0.015) (Figure 3B) but not in the pharyngeal
ones.
A very interesting observation could be made for the 47
HNSCC patients with pN0 tumours (38 laryngeal and 9
pharyngeal): 19 cases showing a high LVD (14 laryngeal
and 5 pharyngeal) had a poorer prognosis than the rest
(p = 0.005) (Figure 3C). Among the group of 38 pN0 lar-
yngeal tumours a high LVD was the only marker of poor
prognosis in univariate analysis (p = 0.03) (Figure 3D).
None of these variables reached statistical significance
when multivariate Cox analysis was performed.
Discussion
In the present study we investigated the existence of
tumour lymphangiogenesis in a cohort of 104 laryngeal/
pharyngeal carcinoma patients and evaluated whether
ILD, PLD or LVD correlated with the presence of lymph
node metastasis; we also addressed the prognostic signif-
icance of the above parameters on the disease specific
and overall survival of these patients.
As previously described, podoplanin was detected in
tumour cells [13] and lymphatic vessels were observed
Table 3 Correlations between lymphatic vessel density and clinicopathologic features in the laryngeal carcinoma
series (N = 54)
LARYNX ILD PLD LVD) Lymphatic Invasion
Frequency 57.41% (31/54) 55.56% (30/54) 87.04% (47/54) 28.30% (15/53)
Mean (S.E.) 10.59 (1.65) 18.47 (2.03) 18.98 (1.56)
Score range 0-41.56 0-60.45 0-44.71
N Mean range p# N Mean (S.E) p¥ N Mean (S.E) p¥ Absent Present Total p*
Anatomic site
Glottis 30 23.45 0.028 30 15.22 (2.43) 0.073 30 16.14 (2.06) 0.042 23 6 29 0.176
Supraglottis 24 32.56 24 22.54 (3.30) 24 22.52 (2.24) 15 9 24
Total 54 54 54 38 15 53
pT
T1-2 28 22.05 0.006 28 15.95 (2.85) 0.2 28 15.98 (2.38) 0.044 25 3 28 0.003
T3-4 26 33.37 26 21.19 (2.86) 26 22.20 (1.84) 13 12 25
Total 54 54 54 38 15 53
Nodal involvement
Free 38 25.38 0.112 38 16.63 (2.23) 0.165 38 17.72 (1.81) 0.219 30 8 38 0.062
Affected 16 32.53 16 22.85 (4.27) 16 21.96 (3.03) 8 7 15
Total 54 54 54 38 15 53
Tumour Stage
I-II 24 20.92 0.004 24 13.95 (2.52) 0.045 24 15.05 (2.35) 0.023 20 4 24 0.073
III-IV 30 32.77 30 22.09 (2.92) 30 22.12 (1.94) 17 11 28
Total 54 54 54 37 15 52
Recurrence
No 43 28.35 0.169 43 17.02 (2.28) 0.218 43 18.60 (1.80) 0.685 29 13 42 0.492
Yes 10 21.20 10 23.55 (4.7) 10 20.28 (3.57) 8 2 10
Total 53 53 53 37 15 52
ILD, Intratumoural Lymphatic Density; PLD, Peritumoural Lymphatic Density; LVD, Lymphatic Vessel Density
S.E., Standard Error
p# (U Mann-Whitney); p¥ (t Student); p* (chi square)
Frequencies (cases with lymph vessels), mean values and score ranges of ILD, PLD and LVD in laryngeal carcinoma population (N=54). Comparison of mean ILD,
PLD and LVD values among different categories of clinico-pathological features. Distribution of tumours according to lymphatic invasion (LI) and
clinicopathological features.
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both within the tumour mass (ILD) and in the peritu-
moural area (PLD)[5,14-17]. Higher ILD correlated with
a more aggressive tumour phenotype and high LVD was
predictor of poor survival (p = 0.045). However, when
laryngeal and pharyngeal tumours were considered sepa-
rately, these associations were observed only in laryngeal
carcinomas (LVD and survival, p = 0.027), suggesting a
different contribution of lymphangiogenesis at different
anatomic sites. While heterogeneous results can be
found in the literature regarding this question,[5,14-17]
our data leave evidence of a more relevant role of lym-
phangiogenesis in the laryngeal carcinoma subgroup.
Anatomic characteristics could account for these differ-
ences. The pharynx is a lymph vessel rich area so that
virtually all tumours arising there might benefit from
this circumstance. In our series 96% pharyngeal tumours
were LVD positive and 90% ILD positive. Thus, no dif-
ferences can be expected to be observed regarding
lymph vessel density impact on outcome. In contrast,
the larynx (specially the glottis) is a lymph vessel poor
region and those tumours able to induce lymphangio-
genesis (57% ILD positive cases in our series) might
show a selective advantage regarding spread and thus a
poorer outcome than those that remain vessel free.
In reference to the existence of dividing cells among
lymphatic endothelial cells, we found evidence of at
least one proliferative endothelial lymphatic cell in some
tumour sections, although their proportion was low.
These results are in line with previous reports that point
to the existence of an active lymphangiogenesis process
in HNSCC[5,15].
The correlation between ILD and nodal involvement
supports the role of intratumoural lymph vessels as a
possible route for the spread of tumours to local lymph
nodes. Interestingly, tumour emboli (LI, lymphatic inva-
sion) were observed within lymphatics in 43% of tumour
samples, a higher frequency than previously reported
[5,15,17,18]. Importantly, LI correlated with tumour
size, nodal involvement, tumour stage and a reduced
survival rate.
Table 4 Correlations between lymphatic vessel density and clinicopathologic features in the laryngeal carcinoma
series (N = 50)
PHARYNX ILD PLD LVD Lymphatic Invasion
Frequency 90% (45/50) 90% (45/50) 96% (48/50) 58% (29/50)
Mean (S.E.) 19.14 (1.97) 27.41 (2.57) 26.47 (1.92)
Score range 0-78.39 0-82.17 8.5 -79.34
N Mean (S.E) p¥ N Mean (S.E) p¥ N Mean range p# Absent Present Total p*
Anatomic site
Hypopharynx 18 19.92 (3.48) 0.8600 18 30.87 (3.91) 0.3470 18 29.67 0.0810 12 6 18 0.0230
Oropharynx 31 19.18 (2.45) 31 25.70 (3.46) 31 22.29 9 22 31
Total 49 49 49 21 28 49
pT
T1-2 11 14.71 (3.53) 0.236 11 27.45 (3.12) 0.993 11 29.18 0.343 4 7 11 0.668
T3-4 39 20.39 (2.30) 39 27.39 (3.11) 39 24.46 17 22 39
Total 50 50 50 21 29 50
Nodal involvement
Free 9 16.30 (3.90) 0.3330 9 26.94 (7.77) 0.3450 9 27.50 0.6550 5 4 9 0.3630
Affected 41 19.77 (2.25) 41 27.51 (2.69) 41 25.06 16 25 41
Total 50 50 50 21 29 50
Tumour Stage
I-II 4 12.12 (7.01) 0.3720 4 19.05 (8.74) 0.3650 4 28.13 0.4280 4 0 4 0.0100
III-IV 41 19.60 (2.29) 41 28.57 (2.99) 41 22.50 14 27 41
Total 45 45 45 18 27 45
Recurrence
No 23 19.19 (2.37) 0.9140 23 26.41 (4.34) 0.7410 23 24.39 0.8480 9 14 23 0.6420
Yes 24 18.73 (3.45) 24 28.24 (3.43) 24 23.63 11 13 24
Total 47 47 47 20 27 47
ILD, Intratumoural Lymphatic Density; PLD, Peritumoural Lymphatic Density; LVD, Lymphatic Vessel Density
S.E., Standard Error
p# (U Mann-Whitney); p¥ (t Student); p* (chi square)
Frequencies (cases with lymph vessels), mean values and score ranges of ILD, PLD and LVD in pharyngeal population (N=50). Comparison of mean ILD, PLD and
LVD values among different categories of clinico-pathological features. Distribution of tumours according to lymphatic invasion (LI) and clinicopathological
features.
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Lymphatic cell proliferation and tumour emboli for-
mation may be rare events, difficult to detect by exam-
ining small sections of archival tissue at a single time
point. Despite this, the detection of proliferating lym-
phatics in carcinoma tissue and of tumour emboli
within lymphatics constitutes considerable evidence for
the presence of active lymphangiogenesis in this type of
malignancy. Additionally, we present evidence of a true
lymphangiogenic process in the larynx, since lymphatics
were detected in pT1 tumours arising in the glottis, a
Figure 2 Proliferation state of lymphatic vessels. Examples of podoplanin positive (green) proliferative (ki-67 positive, red) lymphatic vessels
in an oropharyngeal (A-D and I-L) and a supraglottic carcinoma (E-H). D2-40 positive (green) proliferating tumour mass inside a lymphatic vessel
of a supraglottic carcinoma (M-P) (lymphatic invasion positive case, ki-67 positive embolus, red). First and second columns D2-40 -green- and ki-
67 -red- immunstainings, respectively; third and last columns, DAPI (blue) and merged images. Scale bar, 10 μm.
Table 5 Impact of the lymphatic vessel density on
survival
ALL CASES (N = 104) Larynx (N = 54) Pharynx (N = 50)
Median p Median p Median p
ILD 13.22 0.15 7.56 0.3262 18.42 0.6831
PLD 22.67 0.3898 20.78 0.6321 26.92 0.7139
LVD 22.04 0.045 20.78 0.027 22.98 0.334
LI 0.045 0.015 0.5933
Kaplan Meier disease specific survival analysis p-values for ILD, PLD, LVD -
dichotomized according to their median values - in the whole population,
laryngeal and pharyngeal tumours
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physiologically lymph vessel free site. This observation
would indicate the formation of new vessels in these
cases. On the other hand, the presence of lymphatics in
the pT2-4 glottic tumours would not necessarily point
to this phenomenon, since vessels might also result
from their being entrapped as growing tumours reached
the vessel rich areas, such as the paraglottic space,
supraglottis or subglottis.
Controversial results can be found in the literature
regarding the specific contribution of intra and peri-
tumoural lymphatic vessels to tumour spread. Func-
tional studies in animal models have shown that
Figure 3 Lymphatic Vessel Density and survival. Disease specific survival curves for pharyngolaryngeal squamous carcinoma patients (A) or
laryngeal carcinoma patients (B) stratified by the presence of tumour emboli inside lymphatics. pN0 HNSCC patients (C) or pN0 laryngeal
carcinoma (D) stratified according to LVD (null-low vs. high). The number of patients remaining after every ten/twenty months period is
indicated along each curve. Log-rank test significance is indicated.
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intratumoural lymphatic vessels are compressed and
nonfunctional. However, some studies on human
tumour samples reveal that intratumoural lymphatics
are involved in nodal metastasis and that ILD is a sig-
nificant indicator of poor prognosis[5,14,17]. Other
authors describe an association of high PLD with
shorter disease-free survival,[16,19] whereas a correla-
tion between higher PLD and a more favourable out-
come has also been reported[17]. These
heterogeneous results could arise from the different
methods used to quantify LVD and could reflect sub-
jective factors and the intrinsic difficulties found in
intra vs. peritumoural vessel identification when
studying single tissue sections taken at a single time
point, which might yield a misleading vessel classifica-
tion, limiting the potential value of these variables.
Although both ILD and PLD contribute to tumour
spread to lymph nodes, from our experience, LVD
counting (regardless of their location with respect to
the tumour) is more reproducible and might be a
more reliable marker of poor prognosis, especially
within the laryngeal subgroup.
Remarkably, although nodal involvement had a nega-
tive prognostic value, this prediction could be refined
among the pN0 laryngeal tumour population, according
to their LVD. Thus, significant differences on survival
times were found for cases showing a high LVD (poorer
outcome). This observation was also made in the whole
series of carcinomas but not in the pharyngeal sub-
group, and might be a useful tool in the pN0 laryngeal
cancer patients’ clinical management.
Conclusions
In summary, our results suggest a differential implica-
tion of lymphangiogenesis in tumours arising from dif-
ferent anatomical head and neck sites. We propose that
LVD assessment and tumour emboli detection using the
D2-40 antibody should be considered as potential prog-
nostic tools for laryngeal tumours. This would merit
further large-scale validation analyses for the eventual
future incorporation of these potential markers into
clinical practice.
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